Robert Lakin

Robert Lakin

InvestorPlace Contributor

A journalist — both writer and editor — Robert has covered markets and economies for more than 20 years. His previous gigs include Bloomberg News, where he was emerging markets editor in Tel Aviv, McKinsey & Co. and McDonald & Company Investments, where he was equities research editor.

His deep experience includes covering startups, emerging markets, financial services, and capital markets.

He writes a Substack newsletter, TLV Strategist, which covers the Israel business scene.

Recent Articles

OCGN Stock: The White House News That Has Ocugen Climbing Today

By Robert Lakin, InvestorPlace Contributor

OCGN stock is gaining on Monday following an announcement that the White House will back India in its Covid-19 fight.

CCIV Stock: Is a Middle East Connection Boosting Churchill Capital Today?

By Robert Lakin, InvestorPlace Contributor

Lucid Motors is poised to benefit big from e-mobility initiatives in Saudi Arabia. Recent developments bode well for the CCIV stock SPAC target.

PLTR Stock: The New Government Deal Helping Palantir Gain Today

By Robert Lakin, InvestorPlace Contributor

PLTR stock looks to continue its gains on Thursday following an announcement that its software is included in yet another U.K. contract.

ARVL, FSR, CCIV, TSLA, ACTC: The Biden Plan That Has EV Stocks on Watch Today

By Robert Lakin, InvestorPlace Contributor

Several top EV stocks like ARVL stock and FSR stock are on watch today, following remarks from President Joe Biden about EV spending.

OCGN Stock: The Huge COVAXIN News Sending Ocugen Climbing Today

By Robert Lakin, InvestorPlace Contributor

OCGN stock is gaining Wednesday morning on news that Bharat Biotech's COVAXIN has an overall 78% efficacy rate. Here's what to know.

Load More